Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Trump Says Anthropic No Longer Seen as National Security Threat 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Siemens Healthineers (ETR:SHLG) reported a solid second-quarter performance, with revenue rising 6.8% year-over-year to €5.9 billion, driven by robust demand in its Imaging and Varian segments. The German medical technology company also posted a 25% surge in net income to €537 million and a 19% increase in adjusted EBIT to €982 million, achieving a margin of 16.6%. Basic adjusted earnings per share edged up slightly to €0.56 from €0.55.
Imaging remained the company’s growth engine, with revenue increasing 8.7% to nearly €3.3 billion, led by strong Molecular Imaging and Computed Tomography sales. The segment posted a high EBIT margin of 22.4%, with solid performance in the Americas balancing out softer demand in China and the EMEA region.
Varian revenue surged 12.5% to €1 billion, recovering across all markets. However, its EBIT margin slipped to 13.2% due to an increased share of equipment sales and adverse currency effects. Diagnostics revenue rose 1% to €1.1 billion, with a margin improvement to 6.3%, while Advanced Therapies grew 3.7% to €553 million, delivering an 18.5% margin.
Free cash flow reached €200 million, and the book-to-bill ratio came in at 1.14, signaling strong order intake. Despite this, Siemens Healthineers revised its full-year adjusted EPS guidance to €2.20–€2.50, down from €2.35–€2.50, citing increased geopolitical and trade uncertainties. The company reaffirmed its full-year revenue growth forecast of 5%–6%.
CEO Bernd Montag noted that while core growth drivers remain intact, global volatility could impact performance. Net financial income fell to -€111 million, and the effective tax rate rose to 27%, marginally weighing on earnings. Restructuring and severance costs declined, reflecting ongoing transformation efforts.
